Orphan drugs

孤儿药 斯科普斯 医学 家庭医学 罕见病 业务 谈判 政治学 梅德林 疾病 法学 生物信息学 病理 生物
作者
Francesca Cainelli,Sandro Vento
出处
期刊:The Lancet [Elsevier BV]
卷期号:393 (10181): 1594-1594
标识
DOI:10.1016/s0140-6736(19)30016-9
摘要

Lucio Luzzatto and colleagues1Luzzatto L Hyry HI Schieppati A et al.Outrageous prices of orphan drugs: a call for collaboration.Lancet. 2018; 392: 791-794Summary Full Text Full Text PDF PubMed Scopus (99) Google Scholar (Sept 1, 2018, p 791) have called for collaboration from EU member states on negotiation of orphan drug prices to take advantage of the fact that with 500 million inhabitants, the EU is the largest customer for any new drug. Low-income and middle-income countries (LMICs), with more than 6 billion inhabitants and 360–480 million patients with rare diseases,2Auvin S Irwin J Abi-Aad P Battersby A The problem of rarity: estimation of prevalence in rare disease.Value Health. 2018; 21: 501-507Summary Full Text Full Text PDF PubMed Scopus (38) Google Scholar are in need of orphan drugs and should join forces in this area. Rare diseases cannot continue to be neglected in developing countries, and international collaboration among these countries is vital to change the situation. Screening programmes should be introduced for more diseases, and educational programmes for doctors (especially paediatricians and general practitioners) and nurses should be implemented; these would raise the number of diagnoses and reduce misdiagnoses. Most importantly, more patients with rare diseases for which drugs are available should be treated. Legislations, regulations, and policies for orphan drugs should be drafted and implemented (a review article3Gammie T Lu CY Babar ZU-D Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries.PLoS One. 2015; 10: e0140002Crossref PubMed Scopus (145) Google Scholar failed to identify any pertinent legislation in Latin American and African countries). Patient organisations should be created in LMICs and should play a prominent role in increasing awareness and urging governments to provide treatment for rare diseases, particularly for children. Provision of antiretrovirals to HIV-infected patients in LMICs was considered impossible on economic grounds 20 years ago, and became a reality in 2010; a joint effort from patient organisations and governments could make the provision of orphan drugs to patients in need in the same countries a reality. We declare no competing interests. Outrageous prices of orphan drugs: a call for collaborationFew instances of a single act of legislation have shifted industrial policy in the pharmaceutical industry like the Orphan Drugs Act did when it was signed in the USA in 1983. The Act was written to facilitate the development of drugs for rare diseases and health conditions,1 and the incentives provided by the Act, such as 7 year exclusivity, tax credits of up to 50% of research and development costs, and access to research and development grants, resulted in the US Food and Drug Administration2 (FDA) approving 575 drugs and biological products for rare diseases between 1983 and 2017—a real success. Full-Text PDF Orphan drugsThe Viewpoint by Luzzatto and colleagues1 on drug pricing addresses a very crucial issue because an increasing number of orphan drugs have been marketed in the past decade, and genetic treatments costing more than €300 000 are being made available. Among the determinants of drug pricing reported in the Viewpoint,1 benefit to the patient is the main factor that is typically examined in cost-effectiveness analyses; disease-specific factors are already recognised to influence drug prices because an inverse association exists between treatment cost and disease prevalence. Full-Text PDF Orphan drugsLuzzatto and colleagues1 give three recommendations for pricing orphan drugs. We will focus on the first recommendation (European price negotiation) and on the first part of the second (cost-based pricing). Full-Text PDF Orphan drugs – Authors' replyWe agree with Francesca Cainelli and Sandro Vento that patients with orphan diseases, regardless of location, ought to receive the best treatment available. We share their appeal on behalf of low-income and middle-income countries for access to orphan drugs. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
suodeheng完成签到,获得积分10
刚刚
刚刚
小畅完成签到,获得积分10
1秒前
五本笔记完成签到 ,获得积分10
3秒前
4秒前
K3完成签到,获得积分10
12秒前
颜色渐变完成签到 ,获得积分10
13秒前
量子星尘发布了新的文献求助10
16秒前
1121完成签到 ,获得积分10
16秒前
Joker完成签到,获得积分0
17秒前
小杨完成签到 ,获得积分10
24秒前
25秒前
萧然完成签到,获得积分10
25秒前
hoshizora765完成签到 ,获得积分10
27秒前
关中人完成签到,获得积分10
27秒前
Silence完成签到,获得积分0
36秒前
冷静的访天完成签到 ,获得积分10
38秒前
佐敦完成签到,获得积分10
38秒前
40秒前
woodword完成签到,获得积分10
40秒前
hzhz完成签到,获得积分10
41秒前
莫三颜完成签到,获得积分10
42秒前
肸肸完成签到 ,获得积分10
45秒前
aa完成签到,获得积分10
46秒前
热心市民完成签到 ,获得积分10
46秒前
47秒前
火星上芹菜完成签到,获得积分10
49秒前
靓仔我来帮你完成签到,获得积分10
51秒前
52秒前
风起枫落完成签到 ,获得积分10
52秒前
BenLuo完成签到,获得积分10
53秒前
33完成签到 ,获得积分10
59秒前
健忘数据线完成签到 ,获得积分10
59秒前
Judy完成签到 ,获得积分0
59秒前
savesunshine1022完成签到,获得积分10
59秒前
量子星尘发布了新的文献求助10
1分钟前
道道sy完成签到,获得积分10
1分钟前
温文尔雅完成签到,获得积分10
1分钟前
Jimmy_King完成签到 ,获得积分10
1分钟前
伴奏小胖完成签到 ,获得积分10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976735
求助须知:如何正确求助?哪些是违规求助? 3520831
关于积分的说明 11204951
捐赠科研通 3257684
什么是DOI,文献DOI怎么找? 1798834
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806663